What is it about?
Mesoporous silica nanoparticles for the development of stimuli-responsive DDSs has been paid close attention to. We established the redox and pH dual-stimuli responsive drug delivery system (ZnO@CMS) based on colloidal mesoporous silica nanoparticles (CMS) with ZnO QDs as capping agent in cancer therapy. The drug release from ZnO@CMS might be controlled in redox and pH dual-stimuli conditions, ZnO@CMS had better biocompatibility compared to CMS-SH and might achieve the antitumor effect on cancer cells.
Featured Image
Photo by Alex Stuart on Unsplash
Why is it important?
The in vitro release studies indicated the redox and pH-sensitive drug release behaviors. The hemolysis and BSA adsorption experiments showed that the modification of ZnO QDs on CMS-SH (ZnO@CMS) has better biocompatibility compared to CMS-SH. The cell viability assay exhibited that the ZnO@CMS might achieve a antitumor effect on cancer cells due to the cytotoxicity of ZnO QDs. The ZnO@CMS-DOX showed a higher cellular uptake performance in MCF-7 cells than that of CMS-DOX due to the ZnO QDS as a capping agent blocking the pores of nanoparticles and inhibiting the release of DOX. Therefore, the excellent properties of ZnO@CMS might make it the excellent redox/pH-responsive nanocarrier for broad application in tumor chemotherapy.
Perspectives
I and co-authors were a great pleasure to submit our paper to the Journal. I hope you find this article thought-provoking. Also, I should hope that our work had any help for the other researcher.
Mingxing Liu
Hubei University of Technology
Read the Original
This page is a summary of: Redox/pH dual stimuli-responsive ZnO QDS-gated mesoporous silica nanoparticles as carriers in cancer therapy, IET Nanobiotechnology, May 2019, the Institution of Engineering and Technology (the IET),
DOI: 10.1049/iet-nbt.2019.0031.
You can read the full text:
Contributors
The following have contributed to this page
